Showing results (51-60 of 120) with videos related to

Sort By:
Pageof 12
Oncoimmunology|February 8, 2021
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, et al.
Clinical Lung Cancer|January 17, 2022
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50Liran Holtzman, Mor Moskovitz, Damien Urban, et al.
Molecular Cancer Research : MCR|March 15, 2020
Stromal-MDM2 Promotes Lung Cancer Cell Invasion through Tumor-Host Feedback SignalingIris Kamer, Inbal Daniel-Meshulam, Oranit Zadok, et al.
Cancer Immunology, Immunotherapy : CII|January 23, 2021
Immunotherapy response modeling by ex-vivo organ culture for lung cancerIris Kamer, Elizabeta Bab-Dinitz, Oranit Zadok, et al.
The British Journal of Radiology|June 27, 2025
Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survivalSarit Appel, Lee Wilk, Akram Saad, et al.
Frontiers in Oncology|August 9, 2021
Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy BiomarkersSameh Daher, Yaacov R Lawrence, Elizabeth Dudnik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2018
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass PathwaysDonatella Romaniello, Luigi Mazzeo, Maicol Mancini, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungElizabeth Dudnik, Samuel Kareff, Mor Moskovitz, et al.
Clinical Lung Cancer|June 18, 2015
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24Jair Bar, Keyue Ding, Huijun Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2019
Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective studyJair Bar, Gal Markel, Teodor Gottfried, et al.
Pageof 12